Navigation Links
FundRx Announces Investment in NeuroOne Inc.
Date:3/15/2017

FundRx Inc., an early stage healthcare venture capital firm, today announced that it has invested in NeuroOne Inc., a next generation, platform technology company focused on developing advanced neuromonitoring and neuromodulating products. FundRx participated in a $1.2 million seed round which will be used to accelerate NeuroOne’s lead product, a neurodiagnostic solution for the treatment of epilepsy. NeuroOne’s core technology was developed in partnership with the Mayo Clinic and the University of Wisconsin.

“NeuroOne’s technology platform will add significant value both for payors and patients specifically in the way we manage treatments for epilepsy, Parkinson’s disease, and other neurological disorders. This is an example where innovation in other fields, such as semiconductors, have a direct impact on improving healthcare once the human science catches up,” said Zeshan Muhammedi, CEO at FundRx.

FundRx’s network of neurologists, neurosurgeons and diagnostic experts evaluated NeuroOne through its Peer Review Council process. This Council is an integral part of the FundRx diligence process as it helps evaluate a company’s core scientific merits directly by a large pool of clinical experts while verifying the true business market with industry members.

“Most investors are strictly capital providers. FundRx is different. Not only did they help us secure the capital we need to further develop our lead product, they introduced us to key physicians who helped validate our technology and delivered us valuable market research which we have incorporated into our business strategy and plan for NeuroOne. FundRx has been a true partner and we are honored to be working with them as we enter this next stage of growth,” said Dave Rosa, CEO of NeuroOne.

Muhammedi continued, “In just a short period of time, we have been approached by numerous experts on our platform seeking to work with the NeuroOne team. This further validates the potential of NeuroOne’s technology and its impact on the neurology industry.”

FundRx Background
FundRx’s mission is to accelerate the development of early stage healthcare companies. The firm has built a technology enabled platform which enables companies to access capital but also the diligence, resources, and connections they need to build and grow their businesses. FundRx’s platform consists of 2,600 physicians, scientists, and industry experts from some of the world’s leading institutions including Harvard University, Mt. Sinai Hospital, Stanford University and Tufts University.

To date, FundRx has funded 11 healthcare start-ups including EpiBone, a revolutionary bone reconstruction company; Saferide, an on-demand non-emergency transportation company; Soundbite Medical Solutions, a cardiovascular medical technology company developing a proprietary shockwave technology to address significant unmet clinical needs in interventional cardiology; and SnapMD, a cloud-based virtual care management telemedicine company. FundRx was founded in 2015 by Zeshan Muhammedi, Gurdane Bhutani and Justin Martin.

About NeuroOne
NeuroOne’s mission is to provide comprehensive neuromodulation cEEG monitoring and treatment solutions for patients suffering from epilepsy and other nerve related disorders that result in superior patient outcomes with reduced overall costs. The company is headquartered in Minnetonka, Minnesota and is currently pursuing a near-term FDA approval for its lead product through the 510(k) submission process. For more information visit, http://www.neurooneinc.com.

About FundRx
Founded in 2015 and based in New York, FundRx is an early stage healthcare venture capital firm. The firm seeks to fund, support and build high impact start-up companies pursuing novel research and new models of care. FundRx works closely with physicians, scientists, and industry partners to ensure quality companies receive the resources they need to move their innovations from the lab to the clinic. More information is available at http://www.fundrx.com.

# # #

Contact:
Zeshan Muhammedi
CEO
FundRx
646-751-7634
zeshan(at)fundrx(dot)co

Read the full story at http://www.prweb.com/releases/2017/03/prweb14147121.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. PMG Research Announces Clinical Trial Community with Smart Patients
2. Cellecta, Inc. Announces Upcoming Presentations at the American Association for Cancer Research 2017 Annual Meeting
3. Eurofins Genomics US Announces Commercial Launch of Next Generation DNA Synthesis Service
4. OncoSec Announces First Technology Access Program Agreement with Inhibrx
5. Dove Press Announces Sponsorship of Nanomedicine Academy of Minority Serving Institutions at Northeastern University
6. Northwest Kidney Centers Announces Intention to Grant $15 Million to Jumpstart UW Medicines Center for Dialysis Innovation
7. Integrated Service Solutions, Inc. Announces Expanded Scope of Accreditation by A2LA
8. Aethlon Medical Announces The Conclusion Of Hemopurifier Clinical Study
9. ClinCapture Announces Open House to Celebrate Launch of New EDC Product
10. Acumed LLC Announces Appointment of Sharon Wolfington as President and Chief Executive Officer
11. Rosalind Franklin University announces construction of new Innovation and Research Park
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/10/2019)... ... April 10, 2019 , ... After more than three months ... new kitchen is equipped with updated appliances and modern lighting and fixtures, and will ... , “We’ve seen tremendous growth in the demand for our team-building events ...
(Date:4/8/2019)... and BOSTON (PRWEB) , ... April 08, 2019 ... ... cloud-based enterprise-class unified communications and collaboration solutions, announced today the launch of their ... to an unprecedented range of business and contact-orientated applications while using CT Cloud ...
(Date:4/4/2019)... ... , ... LeadingBiotech, an exclusive event series bringing biopharma CEOs ... CEO conference to be held May 28-29, 2019 at Boston’s Four Seasons Hotel. ... and discussions from past, present and future change-makers. , LeadingBiotech, formerly ...
(Date:3/27/2019)... ... March 27, 2019 , ... Lachman is sponsoring the event on April 1-4, ... Dublin, Ireland. The executive team on site will be available to discuss strategies and ... the agenda this year. , Executives from Lachman participating at this year’s conference include ...
Breaking Biology Technology:
(Date:3/29/2019)... STATION, Texas (PRWEB) , ... March 29, 2019 ... ... prefabricated, flexible cleanroom solutions, for its new multi-product cell therapy facility. The new ... expand GenCure’s manufacturing capabilities, providing new state of the art manufacturing capabilities to ...
(Date:3/25/2019)... ... March 25, 2019 , ... ... of clinical and research genetic testing, today announced a new laboratory services agreement ... precision medicine for cancer. Through this laboratory services agreement, Ambry Genetics and ...
(Date:3/19/2019)... ... March 19, 2019 , ... Nativis, Inc., today ... The name change is effective immediately for the clinical stage, therapeutic device company, ... In making the announcement, Chris Rivera, Chief Executive Officer, said, “the renaming of ...
Breaking Biology News(10 mins):